Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Immunotherapy for advanced renal cell cancer.
C. Coppin
, F. Porzsolt
, A. Awa
, J. Kumpf
, A. Coldman
,
T. Wilt
Medicine - Veteran's Administration Medical Center
Research output
:
Contribution to journal
›
Review article
›
peer-review
442
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Immunotherapy for advanced renal cell cancer.'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Alpha2 Interferon
10%
Angiogenesis Inhibitor
10%
Arm
70%
Bevacizumab
10%
Cancer Cell
100%
Chemotherapy
10%
Clear Cell Renal Cell Carcinoma
30%
Clinical Oncology
10%
Disease Exacerbation
10%
Diseases
10%
Drug Megadose
50%
Enhancer Region
10%
Hazard Ratio
20%
Immunomodulating Agent
10%
Immunotherapy
100%
Interferon Alfa
100%
Interleukin 2
60%
Kidney Cancer
10%
Low Drug Dose
20%
Malignant Neoplasm
10%
Medical Oncology
10%
Metastatic Carcinoma
30%
Nephrectomy
20%
Optimal Drug Dose
10%
Overall Survival
10%
Patient History of Nephrectomy
20%
Placebo
20%
Randomized Controlled Trial
20%
Spontaneous Remission
30%
Subcutaneous Injection
10%
Vasculotropin Antibody
10%
Pharmacology, Toxicology and Pharmaceutical Science
Alpha Interferon
90%
Alpha2 Interferon
9%
Angiogenesis Inhibitor
9%
Bevacizumab
9%
Chemotherapy Regimens
9%
Disease Exacerbation
9%
Diseases
9%
Immunomodulating Agent
9%
Immunotherapy
100%
Interleukin 2
54%
Kidney Cancer
9%
Malignant Neoplasm
100%
Overall Survival
9%
Patient History of Nephrectomy
18%
Placebo
18%
Randomized Controlled Trial
18%
Remission
100%
Renal Cell Carcinoma
27%
Subcutaneous Injection
9%
Vasculotropin Antibody
9%
Keyphrases
Non-immunotherapy
20%